Treatment News : FDA Approves First Drug to Treat Diarrhea in People With HIV

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » January 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


January 3, 2013

FDA Approves First Drug to Treat Diarrhea in People With HIV

The U.S. Food and Drug Administration (FDA) has approved Fulyzaq (crofelemer), the first drug to relieve symptoms of diarrhea that is a side effect of HIV antiretrovirals (ARVs). Intended for use among people with HIV who are taking ARVs and whose diarrhea is not caused by a virus, bacteria or parasite, the drug treats watery diarrhea that is a consequence of electrolyte secretion and water in the gastrointestinal tract.

The new drug is distributed by Salix Pharmaceuticals in Raleigh, North Carolina, according to an FDA statement. It is derived from the sap of the Croton lechleri plant, commonly known as the Peruvian dragon’s blood tree.

The clinical trial that proved the safety and efficacy of Fulyzaq involved 374 HIV-positive participants who were all on stable ARV therapy and had a history of diarrhea lasting a month or longer, with a median of 2.5 watery bowel movements per day. Those whose diarrhea was caused by either an infection or a gastrointestinal disease were not admitted into the trials. With patients randomly assigned to take either Fulyzaq or a placebo two times a day, 17.6 percent of the treatment arm experienced two or fewer watery bowel movements each week while 8 percent of those on the placebo reached this clinical benchmark.

The most common side effects of Fulyzaq are upper respiratory tract infection, bronchitis, cough, flatulence and increased bilirubin levels.

For the FDA release, click here.

Search: FDA, diarrhea, Fulyzaq, crofelemer, Salix Pharmaceuticals

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.